Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus TACE versus TACE alone for advanced hepatocellular carcinoma
ChiCTR-ONRC-11001849Phase 4Recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Time to progression. Started Mar 2010; status: recruiting.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-ONRC-11001849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-11001849.